Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Monge

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Leukemia & Lymphoma|January 5, 2025
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysisGaurav Varma, Lindsay Fogel, Beth Gordon, et al.
Blood Cancer Journal|March 5, 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyMeera Mohan, Jorge Monge, Nishi Shah, et al.
British Journal of Haematology|October 11, 2014
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk diseaseKlaus M Kortüm, Christian Langer, Jorge Monge, et al.
Blood Advances|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myelomaMateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
Ejhaem|December 5, 2022
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatmentMuhamed Baljevic, Cristina Gasparetto, Gary J Schiller, et al.
NPJ Precision Oncology|April 21, 2026
EXaCT-2: an augmented and customizable oncology-focused whole exome sequencing platformPeter Waltman, Pooja Chandra, Ken W Eng, et al.
Vox Sanguinis|June 24, 2026
Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiencyMargaret A Keller, Tanya Powley, Christine Lomas-Francis, et al.
Blood Cancer Journal|March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Leukemia & Lymphoma|January 5, 2025
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysisGaurav Varma, Lindsay Fogel, Beth Gordon, et al.
Blood Cancer Journal|March 5, 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyMeera Mohan, Jorge Monge, Nishi Shah, et al.
British Journal of Haematology|October 11, 2014
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk diseaseKlaus M Kortüm, Christian Langer, Jorge Monge, et al.
Blood Advances|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myelomaMateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
Ejhaem|December 5, 2022
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatmentMuhamed Baljevic, Cristina Gasparetto, Gary J Schiller, et al.
NPJ Precision Oncology|April 21, 2026
EXaCT-2: an augmented and customizable oncology-focused whole exome sequencing platformPeter Waltman, Pooja Chandra, Ken W Eng, et al.
Vox Sanguinis|June 24, 2026
Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiencyMargaret A Keller, Tanya Powley, Christine Lomas-Francis, et al.
Blood Cancer Journal|March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
Pageof 3